# Lorenzo Leoni

> Lorenzo Leoni is a seed investor at Gain Therapeutics backing Software and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Gain Therapeutics](https://shizune.co/investors/profile/gain-therapeutics)
- Total investments: 5
- Last investment: Oct 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/leonilorenzo/

Lorenzo Leoni is a seed investor at Gain Therapeutics focused on Software and Health Care. Lorenzo Leoni is the CEO, Co-Founder, and Managing Partner of TiVentures. He is a former founder of Oculox Technologies.Lorenzo is a serial entrepreneur and founder of 6 biomedical companies in the US and in Europe. He has an extensive network at the academic, financial, and industrial levels in biotech and Medtech. He holds a Ph.D. inbiochemistry from the University of Lausanne and was an Assistant Professor at the Department of Medicine of UCSD, San Diego, working in immunology and oncology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 3 | 60% |
| Health Care | 2 | 40% |
| Medical | 1 | 20% |
| Chemical | 1 | 20% |
| Computer | 1 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 40% |
| Pre-Seed | 1 | 20% |
| Funding Round | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BigOmics | BigOmics Analytics offers a cloud-based self-service data analytics platform for the healthcare industry. | $1.6M |  | Oct 08, 2025 |  |
| InkVivo | InkVivo provides clinicians and healthcare providers with a product delivery system that optimizes treatments. Their manufacturing approach allows users to design implantable patches, tablets, and injectable biomaterials. | $1.4M | Pre-Seed | Aug 13, 2025 |  |
| Delvitech | Delvitech designs, produces and supplies intelligent solutions for automatic optical inspection (AOI)cfor the electronics industry.Delvitech supplies replacement parts, maintenance services and software updates for AOI Trion, Vantage and Symbion. | $8.6M | Venture - Series Unknown | Apr 16, 2024 |  |
| BigOmics | BigOmics Analytics offers a cloud-based self-service data analytics platform for the healthcare industry. | $1.4M | Seed | Oct 01, 2021 |  |
| Artificialy | State-of-the-art customized and maintainable AI solutions that increase real businesses performance | $2M | Seed | Mar 03, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Acequia Capital (AceCap)](https://shizune.co/investors/profile/acequia-capital) — VC Fund, 1 deal together
- [Century Oak Capital](https://shizune.co/investors/profile/century-oak-capital) — VC Fund, 1 deal together
- [Champion Hill Ventures](https://shizune.co/investors/profile/champion-hill-ventures) — VC Fund, 1 deal together
- [Claves Investments](https://shizune.co/investors/profile/claves-investments) — VC Fund, 1 deal together
- [Diffusion Capital Partners](https://shizune.co/investors/profile/diffusion-capital-partners) — VC Fund, 1 deal together
- [Swisscom](https://shizune.co/investors/profile/swisscom) — VC Fund, 1 deal together

## About Gain Therapeutics

VC Fund · Bethesda, United States

Gain Therapeutics is a developer of pharmacological chaperones drugs designed to treat rare metabolic disorders. The company's drugs utilize Minoryx Direct Enzyme Therapy to identify a new generation of uncomplicated adjuvants, enabling clients to help patients stabilize misfolding mutations and restore protein's enzymatic activity. Ittargets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs.Established in 2017 and is headquartered in Bethesda, MD, USA.

5 contacts available at Gain Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Eric Richman | Chief Executive Officer | https://shizune.co/investors/profile/eric-i-richman |
| Lorenzo Leoni | Vice Chairman and Founder | https://shizune.co/investors/profile/lorenzo-leoni |
| Khalid Islam | Co-Founder and Chairman | https://shizune.co/investors/profile/khalid-islam |
| Matthias Alder | Chief Operating Officer | https://shizune.co/investors/profile/matthias-alder-827e |
| Roberto Maj | Head of Development | https://shizune.co/investors/profile/roberto-maj |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Lorenzo Leoni invest in?

Lorenzo Leoni invests primarily in Software, Health Care and Medical startups, most often at Seed and Pre-Seed stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lorenzo Leoni last invest?

The most recent investment recorded for Lorenzo Leoni closed in Oct 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co